方盛制药(603998) - 投资者关系活动记录表

Group 1: Research and Development - The company is currently conducting preclinical research on 13 innovative traditional Chinese medicine projects, covering fields such as gynecology, orthopedics, respiratory medicine, pediatrics, and oncology [1] - The leading projects in terms of progress include Noni Granules, Jianwei Qutong Pills, and Zhilong Tongluo Tablets [1] Group 2: Marketing and Sales Strategy - In 2024, the company plans to strengthen its marketing team and increase investment in team development based on the new strategy of "strong teams, increased performance, established standards, improved quality, focused innovation, and promoted development" [2] - The company is focusing on developing grassroots medical institutions while balancing both hospital and outpatient markets [2] Group 3: Financial Performance and Risk Management - Marketing and academic promotion activities have been operating normally, with the "338 Project" products achieving good sales growth; however, quarterly performance still requires observation [2] - There is a significant uncertainty regarding the company's sales planning, which depends on market conditions, operational environment, and industry policies [2] Group 4: Financing and Dividend Policy - The company currently has no plans for equity financing; any future plans will be announced in accordance with regulations [2] - The company has implemented a proactive and stable cash dividend policy since its listing, conducting 1-2 dividends annually based on actual conditions [2]